Why Download this Impact Report?

A study by Tufts, in collaboration with CluePoints and PwC, found that approximately half of clinical trials use risk-based quality management components on average to document, verify, and resolve study risks and deviations. The  majority of respondents trust that doing so improves clinical trial quality, increases efficiency, and speeds up timelines. 

Given the enthusiasm surrounding the use of RBQM in trials, the major barrier to its adoption seems to be a lack of internal and cross-functional awareness—which is common across small, medium, and large pharmaceutical and biotechnology companies and contract research organizations (CROs).

Download the case study to discover how Tufts CSDD conducted this research and evaluated the responses to determine why the adoption of RBQM remains limited. 

Got a question? Give us a call at +1 617 765 7129, or email contact@cluepoints.com